RNAi Firm Regulus Cuts Price, Boosts Shares in $45M IPO
In a potential sign the initial public offering (IPO) waters may become more treacherous for biotechs during this year's presidential election season, Regulus Therapeutics Inc. slashed the price of its IPO to $4 per share – less than half of the proposed price range of $10 to $12 – while more than doubling the number of shares, from a proposed 4.5 million to 11.3 million.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter